このページは機械翻訳されています。他のページは英語で表示される場合があります。
View in English
ASO Visual Abstract: Neoadjuvant Gemcitabine,Cisplatin,およびNab-Paclitaxel の後の切除への変換:境界線切除可能な CCA:現実世界の探索分析
- Yawen Dong 1,2, Jonas Santol 1,2, Vanja Podrascanin 1,3, Zhihao Li 1,4, Markus Ammann 1,3, Lionel A Kankeu Fonkoua 5, Rondell P Graham 6, Caitlin B Conboy 5, Nguyen H Tran 5, Susanne G Warner 1, Rory L Smoot 1, Patrick P Starlinger 7
- Yawen Dong 1,2, Jonas Santol 1,2, Vanja Podrascanin 1,3
- 1Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
- 2Department of Surgery, HPB Center, Vienna Health Netwoark, Clinic Favoriten and Sigmund Freud Private University, Vienna, Austria.
- 3University Hospital Wiener Neustadt, Wiener Neustadt, Austria.
- 4William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA.
- 5Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
- 6Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
- 7Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA. starlinger.patrick@mayo.edu.
- 0Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
関連する実験動画
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

